PMC:7696151 / 66728-66990
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1977 | 115-118 | Chemical | denotes | HCQ | MESH:D006886 |
| 1978 | 120-134 | Chemical | denotes | sulphasalazine | MESH:D012460 |
| 1996 | 227-247 | Disease | denotes | rheumatoid arthritis | MESH:D001172 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T125 | 227-247 | Phenotype | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/HP_0001370 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T429 | 0-262 | Sentence | denotes | A multicenter, randomized clinical trial analyzed the tolerability and the efficacy of combined therapy, including HCQ, sulphasalazine, MXT, and PRD with respect to the use of a single antirheumatic drug in the caring of early rheumatoid arthritis for two years. |